Examining the impact of the QUARTET USA trial using the translational science benefits model

Guhan Iyer, Danielle Lazar, Abigail S. Baldridge, Jairo Mejia, Clara K. Chow, Namratha R. Kandula, Olutobi A. Sanuade, Linda Rosul, Jody D. Ciolino, Mark D. Huffman

Research output: Contribution to journalArticlepeer-review

Abstract

Evaluation of benefits beyond quantitative academic outputs is essential in determining translational research value. We used the Translational Science Benefits Model (TSBM) to examine the impact of the QUARTET USA trial using 30 benefits across 4 domains: Clinical, Community, Economic, and Policy. We found that the QUARTET USA trial demonstrated impact in six areas within the Clinical, and Community domains and had potential impact in two additional areas within the Community and Economic domains. Use of the TSBM supports the value of the QUARTET USA trial, which can be used as a template for future cardiovascular trials.

Original languageEnglish
Article numbere187
JournalJournal of Clinical and Translational Science
Volume8
Issue number1
DOIs
StatePublished - Oct 31 2024

Keywords

  • hypertension
  • randomized trial
  • Research impact
  • translational science

Fingerprint

Dive into the research topics of 'Examining the impact of the QUARTET USA trial using the translational science benefits model'. Together they form a unique fingerprint.

Cite this